News und Events

National Strategy for Gene- and Cell-Based Therapies

With the aim of providing severely ill patients with new treatment perspectives through gene- and cell-based therapies, and of strengthening Germany’s long-term international competitiveness as a research and innovation hub in this field, around 150 experts from academia, industry, politics, and civil society have joined forces to develop a National Strategy for Gene- and Cell-Based Therapies on behalf of the Federal Ministry for Research, Technology and Spaceflight. The DWI plays an active role through the Leibniz Joint Lab First in Translation (fiT), with its head, Sven Stegemann, serving as the spokesperson for Working Group V – Enhancing Quality and Capacity in GMP Manufacturing.

All information and resources related to the National GCT Strategy can be found at: https://www.nationale-strategie-gct.de/en/